Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Engelhardt

Showing results (171-180 of 227) with videos related to

Pageof 23
Sort By:
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Leukemia Research|September 24, 2020
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathyNora Rebeka Javorniczky, Julius Wehrle, Gabriele Ihorst, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
Leukemia|July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasMaria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
Leukemia & Lymphoma|December 10, 2024
Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO studyWolfgang Knauf, Jens Uhlig, Eyck von der Heyde, et al.
British Journal of Haematology|February 2, 2013
Cytogenetics of extramedullary manifestations in multiple myelomaLisa Billecke, Eva M Murga Penas, Annette M May, et al.
European Journal of Haematology|July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myelomaChristian Straka, Hans Salwender, Stefan Knop, et al.
Annals of Hematology|June 5, 2025
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literatureHanna Löffler, Magdalena Braun, Heike Reinhardt, et al.
Cancer|June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma NetworkFrancesca Gay, Andreas Günther, Massimo Offidani, et al.
Haematologica|July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Pageof 23

Showing results (171-180 of 227) with videos related to

Sort By:
Pageof 23
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Leukemia Research|September 24, 2020
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathyNora Rebeka Javorniczky, Julius Wehrle, Gabriele Ihorst, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
Leukemia|July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasMaria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
Leukemia & Lymphoma|December 10, 2024
Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO studyWolfgang Knauf, Jens Uhlig, Eyck von der Heyde, et al.
British Journal of Haematology|February 2, 2013
Cytogenetics of extramedullary manifestations in multiple myelomaLisa Billecke, Eva M Murga Penas, Annette M May, et al.
European Journal of Haematology|July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myelomaChristian Straka, Hans Salwender, Stefan Knop, et al.
Annals of Hematology|June 5, 2025
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literatureHanna Löffler, Magdalena Braun, Heike Reinhardt, et al.
Cancer|June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma NetworkFrancesca Gay, Andreas Günther, Massimo Offidani, et al.
Haematologica|July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Pageof 23